anti-Lysyl Oxidase-Like 2 (LOXL2) Antikörper

Human Lysyl Oxidase-Like 2 (LOXL2) Interaktionspartner

1. although Loxl2 is expressed in both dermis and epidermis, its function appears largely confined to the epidermis.

2. we report that overexpression of LOXL2 promotes its accumulation in the Endoplasmic Reticulum where it interacts with HSPA5 leading to activation of the IRE1-XBP1 signalling pathway of the ER-stress response.

3. Copper loading robustly activates hLOXL2 and supports lysyl tyrosylquinone formation.

4. LOXL2 might have an important role in CRC.

5. Results revealed that LOXL2 expression was higher in hepatocellular carcinoma (HCC) cell lines and tissues. There was a significant correlation between EMT status and LOXL2 levels indicated that a higher level of LOXL2 may contribute to tumor progression.

6. Plasma LOXL2 was significantly elevated and also strongly correlated with the degree of left atrial fibrosis in Atrial fibrillation patients with normal left ventricular function.

7. LOXL2 may be involved in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and might be helpful in early diagnosis of RA-ILD.

8. LOXL1/LOXL2 gene expression and protein levels were increased in Idiopathic pulmonary fibrosis (IPF) versus non-IPF.

9. This study focused on the relationship between lysyl oxidase (LOX), LOX-like protein 1 (LOXL1), and LOXL2 and pulmonary emphysema pathogenesis.

10. Glomerular LOXL2 was localized to the cytoplasm of podocytes, as determined by double immunofluorescence microscopy using a podocyte marker (synaptopodin). This result was supported by western blot analysis, which demonstrated that LOXL2 protein expression is present in cultured human podocytes and HK2 human proximal tubular cells.

11. Lysyl oxidase like-2 (LOXL2) overexpression differentially regulates signaling pathways in osteoarthritis chondrocytes.

12. our data reveal that the tumor-promoting role of LOXL2 in ESCC is mediated by perturbing the architecture of actin cytoskeleton through its PPIs.

13. HIF-1alpha plays an important role in the development of HCC by promoting HCC metastasis, EMT and VM through up-regulating LOXL2.

14. Participants were evaluated as part of a clinical trial evaluating the safety and efficacy of simtuzumab a humanized monoclonal antibody that inhibits lysyl oxidase-like 2 (LOXL2), an enzyme that contributes to liver fibrosis by catalyzing collagen cross-linkage

15. expression of LOXL2 endowed dormant tumor cells with cancer stem cell-like phenotype driving their transition to metastatic outgrowth and this stem-like phenotype is dependent on epithelial to mesenchymal transition (EMT) that can be driven by the tumor microenvironment.

16. Simtuzumab is a humanized IgG4 monoclonal antibody that inhibits enzymatic activity of LOXL2... inhibition of LOXL2 expression reduced numbers of activated fibroblasts, decreased ECM deposition, inhibited angiogenesis, and prevented tumor cell invasion and metastases

17. higher LOXL2 expression is associated with the invasiveness of pancreatic cancer cells and the low survival rate of pancreatic cancer patients

18. LOXL2 c.C133T is a pathogenic mutation that is responsible for a fraction of familial intracranial aneurysms.

19. data demonstrate that proteolytic processing is an important event that allows LOXL2-mediated crosslinking of basement membrane collagen IV.

20. new LOXL2 splice variant contributes to tumor progression by novel molecular mechanisms different from LOXL2WT

Fruit Fly (Drosophila melanogaster) Lysyl Oxidase-Like 2 (LOXL2) Interaktionspartner

1. Dmloxl-1 and Dmloxl-2 are differentially expressed; active DmLOXL-1 influences gene expression and development

Mouse (Murine) Lysyl Oxidase-Like 2 (LOXL2) Interaktionspartner

1. although Loxl2 is expressed in both dermis and epidermis, its function appears largely confined to the epidermis.

2. LOXL2 controls myofibroblast transformation and migration.

3. The mRNA and protein expression levels of LOXL2 were higher in a mouse model of tubulointerstitial fibrosis compared with in control mice.

4. Findings indicate a pathophysiologic role and function for lysyl oxidase-like protein LOXL2 in breast cancer metastasis.

5. Insulin resistance promotes lysyl oxidase like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.

6. glomerular extracellular matrix. Altogether, we demonstrate that LOXL2 is a novel component of the molecular machinery that forms cross-linked collagen IV networks, which are essential for glomerular basement membrane stability and molecular ultrafiltration function.

7. LOX and LOXL2 may play an important role in the pathogenesis of AMD. Targeting LOXL2 could have a broader efficacy than targeting LOX, by reducing angiogenesis and inflammation, as well as fibrosis.

8. Loss and gain of function analyses combined with in vivo studies in syngeneic breast cancer models demonstrate the participation of LOXL2 and E47 in tumor growth and their requirement for lung metastasis.

9. promoted intrahepatic metastasis by increasing tissue stiffness

10. Findings reveal new insight into the mechanisms of fibroblast activation, a novel function of LOXL2, and further highlight the importance of generating LOXL2-targeted therapies for the prevention of tumor progression and metastasis.

11. The Snail1 transcription factor represses mouse pericentromeric transcription, acting through the H3K4 deaminase LOXL2.

12. The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation.

13. This study provides the first evidence for the role of LOXL2 in regulating angiogenesis through collagen IV scaffolding.

14. LOXL2 promotes chondrocyte differentiation by mechanisms that are likely to include roles as both a regulator and an effector of chondrocyte differentiation

15. The efficacy and safety of LOXL2-specific monoclonal antibody represents a new therapeutic approach with broad applicability in oncologic and fibrotic diseases.

16. LoxL2 is not expressed in MC3T3-E1 cells.

Rabbit Lysyl Oxidase-Like 2 (LOXL2) Interaktionspartner

1. results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.